Loading
A phase 2 trial of adebrelimab, fOLFOX (5-FU, leucovorin, oxaliplatin), capecitabine and bevacizumab (glioblastoma use) in colorectal cancer, run by The Fourth Affiliated Hospital of Zhejiang University School of Medicine, now recruiting.
Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer is a phase 2, interventional study registered as NCT06282445 by The Fourth Affiliated Hospital of Zhejiang University School of Medicine, with a registry enrolment figure of 36 participants, started 2024-03-01 and due to reach its primary completion in 2025-03-01. Interventions recorded: Adebrelimab; Oxaliplatin; Capecitabine; Bevacizumab. Conditions listed: Colorectal Cancer Metastatic. Primary outcome: Progression-free survival. Colorectal eligibility wording from the registry: "Metastatic colorectal cancer confirmed histologically and/or cytologically and initially unresectable". Sites: China. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Adebrelimab, FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents and the tag colorectal-deep-dive.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents and the tag colorectal-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/